- Home
- LDWY vs HOOK Comparison
LDWY vs HOOK Comparison
Compare LDWY & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- HOOK
- Stock Information
- Founded
- LDWY 1990
- HOOK 2011
- Country
- LDWY United States
- HOOK United States
- Employees
- LDWY N/A
- HOOK N/A
- Industry
- LDWY Advertising
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- LDWY Consumer Discretionary
- HOOK Health Care
- Exchange
- LDWY Nasdaq
- HOOK Nasdaq
- Market Cap
- LDWY 9.2M
- HOOK 9.3M
- IPO Year
- LDWY 1991
- HOOK 2019
- Fundamental
- Price
- LDWY $4.90
- HOOK $1.25
- Analyst Decision
- LDWY
- HOOK Buy
- Analyst Count
- LDWY 0
- HOOK 4
- Target Price
- LDWY N/A
- HOOK $10.67
- AVG Volume (30 Days)
- LDWY 6.5K
- HOOK 62.9K
- Earning Date
- LDWY 08-18-2025
- HOOK 08-07-2025
- Dividend Yield
- LDWY N/A
- HOOK N/A
- EPS Growth
- LDWY N/A
- HOOK N/A
- EPS
- LDWY N/A
- HOOK N/A
- Revenue
- LDWY $42,183,000.00
- HOOK $9,351,000.00
- Revenue This Year
- LDWY N/A
- HOOK N/A
- Revenue Next Year
- LDWY N/A
- HOOK N/A
- P/E Ratio
- LDWY N/A
- HOOK N/A
- Revenue Growth
- LDWY 425.12
- HOOK N/A
- 52 Week Low
- LDWY $3.02
- HOOK $0.72
- 52 Week High
- LDWY $5.53
- HOOK $6.77
- Technical
- Relative Strength Index (RSI)
- LDWY 50.82
- HOOK 38.94
- Support Level
- LDWY $4.85
- HOOK $1.23
- Resistance Level
- LDWY $5.12
- HOOK $1.30
- Average True Range (ATR)
- LDWY 0.16
- HOOK 0.06
- MACD
- LDWY -0.05
- HOOK -0.03
- Stochastic Oscillator
- LDWY 7.84
- HOOK 5.97
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.